Nasdaq · Healthcare
Lichen International Ltd (LICN)
As-reported financials and recent SEC filings for Lichen International Ltd, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$809,000
Net income
$-22.0M
Net margin
—
Diluted EPS
$-4.11
ROE
-31.1%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $809,000 | $0 | $0 | $33.8M | $34.3M |
| Gross profit | $-14.6M | — | — | $20.2M | $20.5M |
| Operating income | $-18.1M | $-4.6M | $12.3M | $10.6M | $11.3M |
| Net income | $-22.0M | $-6.1M | $8.3M | $7.8M | $8.5M |
| Diluted EPS | $-4.11 | $-1.16 | $2.13 | $2.32 | $2.53 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
20-F2026-04-28
View on EDGAR →6-K2026-01-07
View on EDGAR →6-K2025-12-11
View on EDGAR →EFFECT2025-12-10
View on EDGAR →CORRESP2025-12-08
View on EDGAR →F-32025-12-02
View on EDGAR →S-82025-11-07
View on EDGAR →6-K2025-11-07
View on EDGAR →Largest Healthcare peers
Go deeper on LICN
Search Lichen International Ltd’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.